Andrew Pollard to Humans
This is a "connection" page, showing publications Andrew Pollard has written about Humans.
Connection Strength
0.297
-
Should we be vaccinating children against COVID-19 in high-income countries? Expert Rev Vaccines. 2021 09; 20(9):1043-1046.
Score: 0.008
-
ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates - Authors' reply. Lancet. 2021 06 12; 397(10291):2248.
Score: 0.008
-
ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors' reply. Lancet. 2020 11 07; 396(10261):1486-1487.
Score: 0.007
-
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021 02; 21(2):e26-e35.
Score: 0.007
-
Why the elderly appear to be more severely affected by COVID-19: The potential role of immunosenescence and CMV. Rev Med Virol. 2020 09; 30(5):e2144.
Score: 0.007
-
Generating the Evidence for Typhoid Vaccine Introduction: Considerations for Global Disease Burden Estimates and Vaccine Testing Through Human Challenge. Clin Infect Dis. 2019 10 15; 69(Suppl 5):S402-S407.
Score: 0.007
-
A Population-based Observational Study of Childhood Encephalitis in Children Admitted to Pediatric Intensive Care Units in England and Wales. Pediatr Infect Dis J. 2019 07; 38(7):673-677.
Score: 0.007
-
Airway response to respiratory syncytial virus has incidental antibacterial effects. Nat Commun. 2019 05 17; 10(1):2218.
Score: 0.007
-
Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults. J Infect. 2019 05; 78(5):382-392.
Score: 0.006
-
Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial. Lancet Infect Dis. 2019 02; 19(2):156-164.
Score: 0.006
-
A systematic review of antimicrobial resistance in Salmonella enterica serovar Typhi, the etiological agent of typhoid. PLoS Negl Trop Dis. 2018 10; 12(10):e0006779.
Score: 0.006
-
Epidemiology and Immune Pathogenesis of Viral Sepsis. Front Immunol. 2018; 9:2147.
Score: 0.006
-
Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV). Clin Infect Dis. 2018 06 18; 67(1):18-24.
Score: 0.006
-
Meningococcal Disease. Ulster Med J. 2018 May; 87(2):81-82.
Score: 0.006
-
Laboratory and molecular surveillance of paediatric typhoidal Salmonella in Nepal: Antimicrobial resistance and implications for vaccine policy. PLoS Negl Trop Dis. 2018 04; 12(4):e0006408.
Score: 0.006
-
Differences in Immunization Site Pain in Toddlers Vaccinated With Either the 10- or the 13-Valent Pneumococcal Conjugate Vaccine. Pediatr Infect Dis J. 2018 04; 37(4):e103-e106.
Score: 0.006
-
Serotype-Specific Correlates of Protection for Pneumococcal Carriage: An Analysis of Immunity in 19 Countries. Clin Infect Dis. 2018 03 05; 66(6):913-920.
Score: 0.006
-
Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007. Vaccine. 2018 02 28; 36(10):1297-1303.
Score: 0.006
-
Trends in meningococcal disease: challenges for vaccine control when disease is rare. Med J Aust. 2017 11 06; 207(9):380-381.
Score: 0.006
-
Intravenous immunoglobulin for the treatment of childhood encephalitis. Cochrane Database Syst Rev. 2017 Oct 02; 10:CD011367.
Score: 0.006
-
Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet. 2017 Dec 02; 390(10111):2472-2480.
Score: 0.006
-
Issues in vaccinology: Present challenges and future directions. Eur J Immunol. 2017 12; 47(12):2017-2025.
Score: 0.006
-
Four Component Meningococcal Capsular Group B Vaccine in Preterm Infants. J Pediatric Infect Dis Soc. 2017 Sep 01; 6(3):309-310.
Score: 0.006
-
Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine. PLoS One. 2017; 12(8):e0183427.
Score: 0.006
-
The Influence of Maternally Derived Antibody and Infant Age at Vaccination on Infant Vaccine Responses : An Individual Participant Meta-analysis. JAMA Pediatr. 2017 07 01; 171(7):637-646.
Score: 0.006
-
Non-specific effects of vaccines: plausible and potentially important, but implications uncertain. Arch Dis Child. 2017 11; 102(11):1077-1081.
Score: 0.006
-
Divergent Memory B Cell Responses in a Mixed Infant Pneumococcal Conjugate Vaccine Schedule. Pediatr Infect Dis J. 2017 May; 36(5):e130-e135.
Score: 0.006
-
Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A Infection in the First Paratyphoid Human Challenge Model. Clin Infect Dis. 2017 04 15; 64(8):1066-1073.
Score: 0.006
-
Memory B cell response to a PCV-13 booster in 3.5year old children primed with either PCV-7 or PCV-13. Vaccine. 2017 05 09; 35(20):2701-2708.
Score: 0.006
-
High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine. Genome Med. 2017 01 30; 9(1):11.
Score: 0.006
-
Blood culture-PCR to optimise typhoid fever diagnosis after controlled human infection identifies frequent asymptomatic cases and evidence of primary bacteraemia. J Infect. 2017 04; 74(4):358-366.
Score: 0.006
-
Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy. Vaccine. 2016 12 07; 34(50):6350-6357.
Score: 0.006
-
Streptococcus pneumoniae carriage prevalence in Nepal: evaluation of a method for delayed transport of samples from remote regions and implications for vaccine implementation. PLoS One. 2014; 9(6):e98739.
Score: 0.005
-
A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty. Lancet Infect Dis. 2014 May; 14(5):426-34.
Score: 0.005
-
Association between population prevalence of smoking and incidence of meningococcal disease in Norway, Sweden, Denmark and the Netherlands between 1975 and 2009: a population-based time series analysis. BMJ Open. 2014 Feb 10; 4(2):e003312.
Score: 0.005
-
Encephalitis in children. Arch Dis Child. 2012 Feb; 97(2):150-61.
Score: 0.004
-
Reactivation of the bacille Calmette-Guérin scar following immune reconstitution during treatment of infant acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2004 Feb; 26(2):112-5.
Score: 0.002
-
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Nat Commun. 2021 08 17; 12(1):5061.
Score: 0.002
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021 09; 8(9):e568-e580.
Score: 0.002
-
Should we delay covid-19 vaccination in children? BMJ. 2021 07 08; 374:n1687.
Score: 0.002
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV. 2021 08; 8(8):e474-e485.
Score: 0.002
-
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021 08 05; 184(16):4220-4236.e13.
Score: 0.002
-
Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial. Lancet Public Health. 2021 06; 6(6):e416-e427.
Score: 0.002
-
T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nat Commun. 2021 04 06; 12(1):2055.
Score: 0.002
-
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021 04 10; 397(10282):1351-1362.
Score: 0.002
-
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 05 20; 384(20):1885-1898.
Score: 0.002
-
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021 04 29; 184(9):2348-2361.e6.
Score: 0.002
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 03 06; 397(10277):881-891.
Score: 0.002
-
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell. 2021 04 15; 184(8):2201-2211.e7.
Score: 0.002
-
The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell. 2021 04 15; 184(8):2183-2200.e22.
Score: 0.002
-
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021 03 13; 397(10278):1023-1034.
Score: 0.002
-
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021 02; 27(2):279-288.
Score: 0.002
-
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021 02; 27(2):270-278.
Score: 0.002
-
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 01 09; 397(10269):99-111.
Score: 0.002
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 12 19; 396(10267):1979-1993.
Score: 0.002
-
Payment in challenge studies: ethics, attitudes and a new payment for risk model. J Med Ethics. 2020 12; 46(12):815-826.
Score: 0.002
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 08 15; 396(10249):467-478.
Score: 0.002
-
Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine. 2020 06 26; 38(31):4783-4791.
Score: 0.002
-
Typhoid-From Past to Future. Clin Infect Dis. 2019 10 15; 69(Suppl 5):S375-S376.
Score: 0.002
-
Bone and joint infections in Oxford: a 10-year retrospective review. Arch Dis Child. 2020 05; 105(5):515-516.
Score: 0.002
-
Classical and Non-classical Presentations of Complement Factor I Deficiency: Two Contrasting Cases Diagnosed via Genetic and Genomic Methods. Front Immunol. 2019; 10:1150.
Score: 0.002
-
Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. Lancet Infect Dis. 2019 07; 19(7):728-739.
Score: 0.002
-
The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations. Vaccine. 2019 05 27; 37(24):3190-3198.
Score: 0.002
-
Strategies to improve detection and management of human parechovirus infection in young infants. Lancet Infect Dis. 2019 02; 19(2):e51-e58.
Score: 0.002
-
Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection. Vaccine. 2018 11 12; 36(46):6988-6994.
Score: 0.002
-
Computing threshold antibody levels of protection in vaccine clinical trials: An assessment of methodological bias. PLoS One. 2018; 13(9):e0202517.
Score: 0.002
-
Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG. Biologicals. 2018 Nov; 56:29-38.
Score: 0.002
-
Incomplete penetrance for isolated congenital asplenia in humans with mutations in translated and untranslated RPSA exons. Proc Natl Acad Sci U S A. 2018 08 21; 115(34):E8007-E8016.
Score: 0.002
-
The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: A systematic review and meta-analysis. J Infect. 2018 11; 77(5):368-378.
Score: 0.002
-
Change in viral bronchiolitis management in hospitals in the UK after the publication of NICE guideline. J Clin Virol. 2018 08; 105:84-87.
Score: 0.002
-
Use of weighted multivariate estimates in trials of multi-serotype vaccines to simplify interpretation of treatment differences. PLoS One. 2018; 13(4):e0196200.
Score: 0.002
-
Viral bronchiolitis management in hospitals in the UK. J Clin Virol. 2018 07; 104:29-33.
Score: 0.002
-
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. Vaccine. 2018 04 19; 36(17):2300-2306.
Score: 0.002
-
Management of suspected paediatric meningitis: a multicentre prospective cohort study. Arch Dis Child. 2018 12; 103(12):1114-1118.
Score: 0.002
-
Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules. CMAJ. 2017 Oct 16; 189(41):E1276-E1285.
Score: 0.001
-
Prevalence and decay of maternal pneumococcal and meningococcal antibodies: A meta-analysis of type-specific decay rates. Vaccine. 2017 10 13; 35(43):5850-5857.
Score: 0.001
-
The STRATAA study protocol: a programme to assess the burden of enteric fever in Bangladesh, Malawi and Nepal using prospective population census, passive surveillance, serological studies and healthcare utilisation surveys. BMJ Open. 2017 07 02; 7(6):e016283.
Score: 0.001
-
An Appraisal of the Clinical Features of Pediatric Enteric Fever: Systematic Review and Meta-analysis of the Age-Stratified Disease Occurrence. Clin Infect Dis. 2017 Jun 01; 64(11):1604-1611.
Score: 0.001
-
An evaluation of purified Salmonella Typhi protein antigens for the serological diagnosis of acute typhoid fever. J Infect. 2017 08; 75(2):104-114.
Score: 0.001
-
Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency. J Clin Invest. 2017 May 01; 127(5):1991-2006.
Score: 0.001
-
Policy making for vaccine use as a driver of vaccine innovation and development in the developed world. Vaccine. 2017 03 07; 35(10):1380-1389.
Score: 0.001
-
30-year trends in admission rates for encephalitis in children in England and effect of improved diagnostics and measles-mumps-rubella vaccination: a population-based observational study. Lancet Infect Dis. 2017 04; 17(4):422-430.
Score: 0.001
-
Host genetic factors and vaccine-induced immunity to hepatitis B virus infection. PLoS One. 2008 Mar 26; 3(3):e1898.
Score: 0.001